Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis

A. Yardley, Denise; Noguchi, Shinzaburo; I. Pritchard, Kathleen; A. Burris, Howard; Baselga, José; Gnant, Michael; N. Hortobágyi, Gabriel; Campone, Mario; Pistilli, Barbara; Piccart, Martine; Melichar, Bohuslav; Petráková, Katarína; P. Arena, Francis; Erdkamp, Frans; A. Harb, Wael; Feng, Wentao; Cahana, Ayelet; Taran, Tetiana; Lebwohl, David; S. Rugo, Hope

doi:10.1007/s12325-013-0060-1

Public

Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis

Published in Advances in Therapy • Oct 1, 2013

Authors:

Denise A. Yardley

Shinzaburo Noguchi

Kathleen I. Pritchard

Abstract

INTRODUCTION: Effective treatments for hormone-receptor-positive (HR(+)) breast cancer (BC) following relapse/progression on nonsteroidal aromatase inhibitor (NSAI) therapy are needed. Initial Breast Cancer Trials of OraL EveROlimus-2 (BOLERO-2) trial data demonstrated that everolimus and exemestane...

Subject

Exemestane

Everolimus

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!